Receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors have been reported in a Shanghai Institute of Organic Chemistry patent as potentially useful for the treatment of cancer, atopic dermatitis, psoriasis, macular degeneration, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel and Alzheimer’s disease, among others.
Research at Nanjing Minova Pharmaceutical Co. Ltd. has led to the development of water-soluble allopregnanolone derivatives acting as prodrugs and reported to be useful for the treatment of Alzheimer’s disease, epilepsy, traumatic brain injury, post-traumatic stress, seasonal mood disorder, essential tremor, dysthymia and postpartum depression, among others.
Researchers at Tuojie Biotech (Shanghai) Co. Ltd. have developed substituted 1,4-dihydro-1,6-naphthyridine amides characterized as mineralocorticoid receptor (MR) antagonists and reported to be useful for the treatment of hypertension, aldosteronism and heart failure.
A recent F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes compounds reported to be useful for the treatment of Escherichia coli infection.
Researchers from Attralus Inc. reported preclinical data for AT-04, a novel peptibody designed to bind neuropathologic fibrillar aggregates in the brains of patients with Alzheimer’s disease (AD).
The common pathological pathway in progressive chronic kidney disease (CKD) is tissue fibrosis and chemokine receptor type 4 (CXCR4) plays a key role in the development of fibrosis.
Ocean Biomedical Inc. announced it will be targeting its pulmonary fibrosis treatment candidate OCF-203 as a novel therapeutic for fatal pulmonary fibrotic conditions caused by Hermansky-Pudlak syndrome (HPS).
Abbvie Inc. recently disclosed the discovery and structure of the anti-tumor necrosis factor (TNF) glucocorticoid receptor modulator (GRM) immunology antibody-drug conjugate (iADC) ABBV-154. The drug is in phase II clinical development as a subcutaneous treatment for rheumatoid arthritis and polymyalgia rheumatica, and as a subcutaneous or intravenous treatment for active Crohn’s disease.
Promis Neurosciences Inc. has submitted an IND application to the FDA for PMN-310 for the treatment of Alzheimer’s disease. PMN-310 is a monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-β (Aβ) that are believed to be a major driver of AD, as opposed to monomers or plaque.
Murine models are primarily used in Alzheimer’s disease (AD) research, but differences between rodents and primates may prevent a true understanding of the mechanisms of the disease.
RSS
